EU approves Bavencio (avelumab) to treat metastatic Merkel cell carcinoma.- Merck KGaA + Pfizer.
Merck and Pfizer Inc. announced that the European Commission (EC) has grantedmarketing authorization for Bavencio (avelumab) as a monotherapy for the treatment of adult patients with metastatic Merkel cell carcinoma (mMCC), a rare and aggressive skin cancer. Bavencio will have marketing authorization in the 28 countries of the European Union (EU) in addition to Norway, Liechtenstein and Iceland.
Bavencio is expected to become commercially available to patients in Europe by prescription within the coming months, with initial launches in Germany UK expected as early as October 2017.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins